Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Able to read, speak, and understand English~* Male or female, 35-70 years old (inclusive)~* Total Fasting Plasma Cholesterol of \>180 mg/dl~* Currently taking statin medications.~* Willing to maintain AHA Step 1 diet for the duration of the study.~Exclusion Criteria:~* Any subject who is taking vitamin E supplements or taking any antibiotics or other medication or dietary supplement which could interfere with the action of tocotrienols.~* Any subject who is taking cholesterol lowering medications other than statins.~* Any subject who has lost \>5% of their body weight during the past 3 months.~* Any subjects with a history of gastrointestinal surgery, diabetes mellitus, or other serious medical condition, such as chronic hepatitis or renal disease, bleeding disorder, congestive heart disease, chronic diarrhea disorders, myocardial infarction, coronary artery bypass graft, angioplasty within 6 months prior to screening, current diagnosis of uncontrolled hypertension (defined as BP \>160mmHg, diastolic BP\>95mmHg), active or chronic gastrointestinal disorders, bulimia, anorexia, laxative abuse, or endocrine diseases (except thyroid disease requiring medication) as indicated by medical history or routine physical examination.~* Major surgery within 12 weeks prior to subject randomization and/or screening, especially cardiac surgery~* Is currently a smoker who has a therapeutic plan to quit smoking anytime during the study period; or if not a current smoker, has quit smoking within the past 3 months.~* Known HIV positive or known immunocompromised condition (e.g. MV, organ transplantation, treatment with immunosuppressant medications).~* Clinical evidence of current malignancy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia.~* Currently receiving systemic chemotherapy and/or radiotherapy.~* Active bleeding.~* Subject has any disorder (excluding illiteracy or visual impairment) that compromises the ability of the subject to give written informed consent and/or to comply with study procedures.~* In the opinion of the study investigator has a risk of non-compliance with study procedures, or cannot read, understand or complete study related materials.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Gamma Delta Tocotrienols - Low Dose (Type: ACTIVE_COMPARATOR): 33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (63mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
- Gamma Delta Tocotrienols - High Dose (Type: ACTIVE_COMPARATOR): 33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the TRF (127mg) arm of the study to evaluate the cholesterol suppressive actions of TRF. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.
- Sugar Pill (Type: PLACEBO_COMPARATOR): 33 subjects with cholesterol level (\>180 mg/dl), ages 35-70, currently taking statins who meet all of the eligibility criteria in the screening phase of the study will be assigned to the Placebo arm of the study to evaluate the cholesterol suppressive actions of Placebo. Subjects will be asked to take 2 tablets per day and to maintain the American Heart Association (AHA) diet for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).